Wang et al. found that MDM4/MDM2 double knockdown combined with trametinib enhanced P53 activation, thereby exerting antitumor effects through the induction of the G1 blockade and apoptosis in wild-type TP53 colorectal cancers with aberrant KRAS signaling [74]. The gene discussed is KRAS; the disease is colorectal cancer.